Price movement over the last 24 hours
Alcon AG vs Plby Group Inc — how do they compare? Alcon AG trades at $66.85 (market cap $32.69B), while Plby Group Inc trades at $1.14 (market cap $136.40M). The key difference: Alcon AG is far larger — about 239.7× Plby Group Inc's market cap, and Alcon AG pays a 0.54% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals.
| ALC | PLBY | |
|---|---|---|
Market Cap | $32.69B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $92.22 | $2.71 |
52-Week Low | $62.02 | $1.18 |
Enterprise Value | $36.28B | $284.21M |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
PLBY trades at $1.18, down 6.35% today, reflecting ongoing volatility. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company has improved its net loss significantly from -$278M in 2022 to -$13M in 2025, with revenue stabilizing around $121M. Recent news highlights inclusion in Russell indexes and a share repurchase program, signaling management confidence. Cash flow turned positive in 2024-2025 after years of negative operational cash flow, though high debt remains a concern.
The outlook is cautiously optimistic due to improving EBITDA and analyst buy ratings (75%), but risks include persistent net losses, high debt-to-asset ratio near 60%, and competitive pressures in leisure branding. Investment appeal hinges on continued margin improvement and debt management, with current valuation metrics like P/S of 1.05 suggesting potential if execution succeeds.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →